A multicenter, randomized, double-blind, double-dummy, placebo-controlled, multi-dose study comparing the efficacy and safety of subcutaneous TEV-48125 with placebo for the preventive treatment of chronic migraine

被引：0

作者：

Bigal, M. ^{[1
]}

Edvinsson, L. ^{[2
]}

Rapoport, A. ^{[3
]}

Lipton, R. ^{[4
]}

Spierings, E. ^{[5
]}

Diener, H. ^{[6
]}

Ma, M. ^{[7
]}

Hudson, J. ^{[8
]}

Silberstein, S. ^{[9
]}

机构：

[1] Teva Pharmaceut, Clin Dev, Frazer, PA USA

[2] Lund Univ, Med, Lund, Sweden

[3] UCSF, Neurol, Palo Alto, CA USA

[4] Albert Einstein Coll Med, Neurol, New York, NY USA

[5] MedVadis Res, Clin Res, Boston, MA USA

[6] Essen Headache Ctr, Neurol, Essen, Germany

[7] Teva Pharmaceut, Stat, Frazer, PA USA

[8] FutureSearch Trials Neurol, Neurol, Austin, TX USA

[9] Jefferson Headache Ctr, Neurol, Philadelphia, PA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

LO-05

引用

页码：1226 / 1226

页数：1